Vemlidy 25 mg film-coated tablets.
Sponsors
Helse Bergen HF, Karolinska University Hospital, Gilead Sciences Inc., Ribocure Pharmaceuticals AB
Conditions
Chronic Hepatitis BChronic hepatitis D virus infectionMultiple sclerosishepatitis D
Phase 2
A Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide (TAF) in Children and Adolescent Subjects with Chronic Hepatitis B Virus Infection
SuspendedCTIS2023-506143-42-00
Start: 2018-05-16Target: 7Updated: 2025-02-28
Tenofovir Alafenamide Fumarate and Epstein-Barr virus activity in people with MS – The TAF-MS study
CompletedCTIS2023-503814-62-00
Start: 2024-02-06End: 2025-11-14Target: 50Updated: 2024-11-08
A phase 2a, multicentre trial to evaluate the efficacy, safety and pharmacokinetics of RBD1016 in participants with chronic hepatitis D virus infection, including a randomized, single-blinded, placebo-controlled exploratory part
Active, not recruitingCTIS2023-509007-33-00
Start: 2024-08-21Target: 15Updated: 2025-12-19